VKTX: SEC Form 8-K filed by Viking Therapeutics Inc.
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for VKTX
Across the 27 sessions after earlier VKTX headlines, the stock closed higher 12 times and lower 15 times, with a median move of 3.2% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | VKTX | SPY |
|---|---|---|---|
| Oct 29, 2026 | Viking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update | +5.9% | -0.4% |
| Oct 22, 2026 | Viking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026 | -2.1% | -1.2% |
| Oct 15, 2026 | UBS initiated coverage on Viking Therapeutics with a new price target | +7.5% | +0.3% |
| Oct 14, 2026 | Viking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity | -4.4% | -1.1% |
| Oct 6, 2026 | Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity | -3.1% | +0.5% |
| Sep 29, 2026 | Viking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes | -3.7% | -0.2% |
Quantisnow market dataNASDAQ
VKTX
Viking Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2015
Get push alerts for VKTX
Full VKTX profile on Quantisnow Follow VKTX and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time